Using meta-regression in performing indirect-comparisons: comparing escitalopram with venlafaxine XR

References

• Song F, Glenny AM, Altman DG. Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery. Control Clin Trials 2000;21:488–97
   Google Scholar
• Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analysis. BMJ 2003;326:472–7
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50: 683–91
   PubMed Web of Science ®Google Scholar
• Sauriol L, Laporta M, Edwardes MD, et al. Meta-analysis comparing newer antipsychotic dugs for the treatment of schizophrenia: evaluating the indirect approach. Clin Therapeut 2001;23:942–56
   PubMed Web of Science ®Google Scholar
• Rubin D. A new perspective. In: Wachter KW, Straf ML, editors. The future of meta-analysis. New York: Russell Sage Foundation, 1990 pp.155–65
   Google Scholar
• Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9: 1–134
   PubMed Web of Science ®Google Scholar
• van Houwelingen HC, Arends LR, Stijnen T. Tutorial in biostatistics advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002;21:589–624
   Google Scholar
• SAS Institute Inc., Cary, NC 27513–2414 USA
   Google Scholar
• Montgomery SA, Huusom AKT, Bothmer J. A randomized study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50:57–64
   Google Scholar
• Bielski RJ, Ventura D, Chang C. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatr 2004;65: 1190–6
   Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. New York: Academic Press, 1969
   Google Scholar
• Cunningham LA; venlafaxine XR 208 study group. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann Clin Psychiatr 1997;9:157–64
   Google Scholar
• Thase ME; venlafaxine XR 209 study group. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. J Clin Psychiatr 1997;58: 393–8
   Google Scholar
• Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999;56:171–81
   PubMed Web of Science ®Google Scholar
• Silverstone PH, Ravindran A; venlafaxine XR 360 study group. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatr 1999;60:22–8
   Google Scholar
• Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/ day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17: 95–102
   Google Scholar
• Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatr 2002;63:1–6
   Google Scholar
• Wightman D, Horrigan JP, Modell JG, et al. The tolerability and safety of bupropion XL versus escitalopram in the treatment of major depressive disorder. Poster presented at the 13th congress of the Association of European Psychiatrists (AEP), Munich, Germany, 2–6 April 2005
   Google Scholar
• Alexopoulos G, Gordon J, Zhang D. A placebo-controlled trial of escitalopram and sertraline in the treatment of major depressive disorder. Poster presented at the American College of Neuropsychopharmacology (ACNP), San Juan, Puerto Rico, 12–16 December 2004
   Google Scholar
• Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003 18:211–7
   Google Scholar
• Ninan PT, Ventura D, Wang J. Escitalopram is effective and well tolerated in the treatment of severe depression. Poster presented at the Congress of the American Psychiatric Association, San Francisco, CA, 17–22 May 2003
   Google Scholar
• Sauriol L, Laporta M, Edwardes MD, et al. Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach. Clin Ther 2001;23:942–56
   PubMed Web of Science ®Google Scholar
• Norman GR, Gwadry Sridar F, Guyatt GH, et al. Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Medical Care 2001;39:1039–47
   PubMed Web of Science ®Google Scholar
• Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatr 2002;180:396–404
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatr Neurosci 2006;31:122–31
   Google Scholar
• Thompson S, Higgins J. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559–73
   PubMed Web of Science ®Google Scholar